Skip to main content
Erschienen in: Journal of Nuclear Cardiology 6/2022

24.05.2022 | Editorial

The promise of hypericin: a tracer for acute myocardial infarction

verfasst von: Mani Salarian

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Excerpt

Myocardial infarction (MI) and subsequent heart failure (HF) is a leading cause of morbidity and mortality worldwide.13 Acute myocardial infarction (AMI) is usually caused by a thrombus blocking an artery or a bypass graft, characterized by sudden decrease in blood flow to the myocardium, leading to heart failure and death.4,5 The irreversible injury in MI originates from severe and sustained myocardial ischemia and typically occurs as a result of rupture or erosion of an epicardial coronary artery plaque, which initiates superimposed thrombosis and occlusion of the coronary artery. Alternatively, in the presence of coronary atherosclerosis, myocardial infarction can occur when unfavorable hemodynamics redistribute blood flow away from a myocardial region supplied by a stenotic coronary artery.6
Literatur
1.
Zurück zum Zitat Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013;6:606‐19.CrossRef Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013;6:606‐19.CrossRef
2.
Zurück zum Zitat Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: A compass for global action. J Am Coll Cardiol 2020;76:2980‐1.CrossRef Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: A compass for global action. J Am Coll Cardiol 2020;76:2980‐1.CrossRef
3.
Zurück zum Zitat Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982‐3021.CrossRef Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982‐3021.CrossRef
4.
Zurück zum Zitat Golforoush P, Yellon DM, Davidson SM. Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. Basic Res Cardiol 2020;115:73.CrossRef Golforoush P, Yellon DM, Davidson SM. Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. Basic Res Cardiol 2020;115:73.CrossRef
5.
Zurück zum Zitat Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: New targets and approaches. Nat Rev Drug Discov 2020;19:333‐52.CrossRef Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: New targets and approaches. Nat Rev Drug Discov 2020;19:333‐52.CrossRef
6.
Zurück zum Zitat Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 2020;17:773‐89.CrossRef Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 2020;17:773‐89.CrossRef
7.
Zurück zum Zitat Banerjee S, Pillai MR, Ramamoorthy N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med 2001;31:260‐77.CrossRef Banerjee S, Pillai MR, Ramamoorthy N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med 2001;31:260‐77.CrossRef
8.
Zurück zum Zitat Christian TF, Behrenbeck T, Gersh BJ, Gibbons RJ. Relation of left ventricular volume and function over one year after acute myocardial infarction to infarct size determined by technetium-99m sestamibi. Am J Cardiol 1991;68:21‐6.CrossRef Christian TF, Behrenbeck T, Gersh BJ, Gibbons RJ. Relation of left ventricular volume and function over one year after acute myocardial infarction to infarct size determined by technetium-99m sestamibi. Am J Cardiol 1991;68:21‐6.CrossRef
9.
Zurück zum Zitat Sciagra R, Bolognese L, Rovai D, Sestini S, Santoro GM, Cerisano G, et al. Detecting myocardial salvage after primary PTCA: Early myocardial contrast echocardiography versus delayed sestamibi perfusion imaging. J Nucl Med 1999;40:363‐70. Sciagra R, Bolognese L, Rovai D, Sestini S, Santoro GM, Cerisano G, et al. Detecting myocardial salvage after primary PTCA: Early myocardial contrast echocardiography versus delayed sestamibi perfusion imaging. J Nucl Med 1999;40:363‐70.
10.
Zurück zum Zitat Dong J, Ndrepepa G, Schmitt C, Mehilli J, Schmieder S, Schwaiger M, et al. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. Circulation 2002;105:2946‐9.CrossRef Dong J, Ndrepepa G, Schmitt C, Mehilli J, Schmieder S, Schwaiger M, et al. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. Circulation 2002;105:2946‐9.CrossRef
11.
Zurück zum Zitat Fujiwara S, Takeishi Y, Hirono O, Fukui A, Okuyama M, Yamaguchi S, et al. Reverse redistribution of 99m Tc-sestamibi after direct percutaneous transluminal coronary angioplasty in acute myocardial infarction: Relationship with wall motion and functional response to dobutamine stimulation. Nucl Med Commun 2001;22:1223‐30.CrossRef Fujiwara S, Takeishi Y, Hirono O, Fukui A, Okuyama M, Yamaguchi S, et al. Reverse redistribution of 99m Tc-sestamibi after direct percutaneous transluminal coronary angioplasty in acute myocardial infarction: Relationship with wall motion and functional response to dobutamine stimulation. Nucl Med Commun 2001;22:1223‐30.CrossRef
12.
Zurück zum Zitat Kumita S, Seino Y, Cho K, Nakajo H, Toba M, Fukushima Y, et al. Assessment of myocardial washout of Tc-99m-sestamibi in patients with chronic heart failure: Comparison with normal control. Ann Nucl Med 2002;16:237‐42.CrossRef Kumita S, Seino Y, Cho K, Nakajo H, Toba M, Fukushima Y, et al. Assessment of myocardial washout of Tc-99m-sestamibi in patients with chronic heart failure: Comparison with normal control. Ann Nucl Med 2002;16:237‐42.CrossRef
13.
Zurück zum Zitat Boschi A, Uccelli L, Marvelli L, Cittanti C, Giganti M, Martini P. Technetium-99m radiopharmaceuticals for ideal myocardial perfusion imaging: Lost and found opportunities. Molecules 2022;27. Boschi A, Uccelli L, Marvelli L, Cittanti C, Giganti M, Martini P. Technetium-99m radiopharmaceuticals for ideal myocardial perfusion imaging: Lost and found opportunities. Molecules 2022;27.
14.
Zurück zum Zitat Gibbons RJ. Tc-99m SPECT sestamibi for the measurement of infarct size. J Cardiovasc Pharmacol Ther 2011;16:321‐31.CrossRef Gibbons RJ. Tc-99m SPECT sestamibi for the measurement of infarct size. J Cardiovasc Pharmacol Ther 2011;16:321‐31.CrossRef
15.
Zurück zum Zitat Jiang B, Wang J, Ni Y, Chen F. Necrosis avidity: A newly discovered feature of hypericin and its preclinical applications in necrosis imaging. Theranostics 2013;3:667‐76.CrossRef Jiang B, Wang J, Ni Y, Chen F. Necrosis avidity: A newly discovered feature of hypericin and its preclinical applications in necrosis imaging. Theranostics 2013;3:667‐76.CrossRef
16.
Zurück zum Zitat Cona MM, Feng Y, Li Y, Chen F, Vunckx K, Zhou L, et al. Comparative study of iodine-123-labeled hypericin and (99m)Tc-labeled hexakis [2-methoxy isobutyl isonitrile] in a rabbit model of myocardial infarction. J Cardiovasc Pharmacol 2013;62:304‐11.CrossRef Cona MM, Feng Y, Li Y, Chen F, Vunckx K, Zhou L, et al. Comparative study of iodine-123-labeled hypericin and (99m)Tc-labeled hexakis [2-methoxy isobutyl isonitrile] in a rabbit model of myocardial infarction. J Cardiovasc Pharmacol 2013;62:304‐11.CrossRef
17.
Zurück zum Zitat Jiang C, Li Y, Jiang X, Yao N, Gao M, Zhang X, et al. Hypericin as a marker for determination of myocardial viability in a rat model of myocardial infarction. Photochem Photobiol 2014;90:867‐72. Jiang C, Li Y, Jiang X, Yao N, Gao M, Zhang X, et al. Hypericin as a marker for determination of myocardial viability in a rat model of myocardial infarction. Photochem Photobiol 2014;90:867‐72.
18.
Zurück zum Zitat Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 2006;33:595‐601.CrossRef Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 2006;33:595‐601.CrossRef
19.
Zurück zum Zitat Cona MM, Li J, Feng Y, Chen F, Verbruggen A, Witte P, et al. Targetability and biodistribution of radioiodinated hypericin: Comparison between microdosing and carrier-added preparations. Anticancer Agents Med Chem 2014;14:852‐61.CrossRef Cona MM, Li J, Feng Y, Chen F, Verbruggen A, Witte P, et al. Targetability and biodistribution of radioiodinated hypericin: Comparison between microdosing and carrier-added preparations. Anticancer Agents Med Chem 2014;14:852‐61.CrossRef
20.
Zurück zum Zitat Yang S, Ma J, Li T, Wang P, Wang X, Zhang J et al. Radioiodinated hypericin as a tracer for detection of acute myocardial infarction: SPECT-CT imaging in a swine model. J Nucl Cardiol 2022. Yang S, Ma J, Li T, Wang P, Wang X, Zhang J et al. Radioiodinated hypericin as a tracer for detection of acute myocardial infarction: SPECT-CT imaging in a swine model. J Nucl Cardiol 2022.
Metadaten
Titel
The promise of hypericin: a tracer for acute myocardial infarction
verfasst von
Mani Salarian
Publikationsdatum
24.05.2022
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 6/2022
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-022-03004-6

Weitere Artikel der Ausgabe 6/2022

Journal of Nuclear Cardiology 6/2022 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.